Grant Yonehiro - 28 Jan 2026 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Reporting relationship: Chief Operating Officer
Issuer ticker: BOLT
Reported as of: 28 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:32:18 UTC
Prior SEC filing: 16 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ William P. Quinn, Attorney-in-Fact

Key filing fact

Grant Yonehiro filed Form 4 for Bolt Biotherapeutics, Inc. (BOLT) on 04 Feb 2026.

Key facts

This page summarizes Grant Yonehiro's Form 4 filing for Bolt Biotherapeutics, Inc. (BOLT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:32.

Change

Previous filing in this sequence was filed on 16 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001428666 Primary reporting owner

Yonehiro Grant

Relationship: Chief Operating Officer
Address: C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY
Signature: /s/ William P. Quinn, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLT transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 28 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $6.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026.